British Gene Therapy Company Takes Steps Toward Cancer Vaccine

Article

LONDON-Oxford BioMedica Plc, a gene therapy company spun from Oxford University, has announced they are making progress in an anti-cancer vaccine.

TroVax, designed to stimulate a patient's immune system to destroy cancer cells, has been tested in phase1/11 studies. Patients involved in the study did develop an immune response against a tumor antigen in colorectal cancer. The vaccine works by encoding the protein OBA1, which naturally exists on the surface of many tumor cells, and basically teaching the immune system to fight these protein cells when they are recognized.

People involved in the study were divided into three dosage groups of the vaccine. The first study's results are from the low dosage group, with the other reports expected to be published next year.

While officials from the company are optimistic the vaccine will be successful, they also warn that it has not yet been shown to treat human cancer.

Information from www.givenimaging.com, Reuters Health

Newsletter

Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.

Recent Videos
David J. Weber, MD, MPH, president of the Society for Healthcare Epidemiology of America
Brenna Doran PhD, MA, hospital epidemiology and infection prevention for the University of California, San Francisco, and a coach and consultant of infection prevention; Jessica Swain, MBA, MLT, director of infection prevention and control for Dartmouth Health in Lebanon, New Hampshire; and Shanina Knighton, associate professor at Case Western Reserve University School of Nursing and senior nurse scientist at MetroHealth System in Cleveland, Ohio
Brenna Doran PhD, MA, hospital epidemiology and infection prevention for the University of California, San Francisco, and a coach and consultant of infection prevention; Jessica Swain, MBA, MLT, director of infection prevention and control for Dartmouth Health in Lebanon, New Hampshire; and Shanina Knighton, associate professor at Case Western Reserve University School of Nursing and senior nurse scientist at MetroHealth System in Cleveland, Ohio
© 2025 MJH Life Sciences

All rights reserved.